BioCentury | Nov 20, 2020
Finance

Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable,  China deal for AUM-Newsoara and Qiming’s $1.2B fund

...company raises $91M series CMedable Inc. raised $91 million in a series C round led by Sapphire...
BioCentury | Nov 9, 2018
Clinical News

Clearside discontinues combo therapy for retinal vein occlusion

...retinal vein occlusion (RVO) after the combination missed the primary endpoint in the Phase III SAPPHIRE...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...Submit NDA YE18 Clearside Biomedical Inc. (NASDAQ:CLSD) Zuprata Retinal vein occlusion (RVO) Top-line Ph III SAPPHIRE...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...Biomedical Inc. (NASDAQ:CLSD) Triamcinolone acetonide Macular edema associated with retinal vein occlusion (RVO) Ph III SAPPHIRE...
BioCentury | Nov 17, 2017
Company News

Pfizer ends JV with Hisun

...Pfizer Inc. (NYSE:PFE) sold its 49% stake in Chinese JV Hisun-Pfizer Pharmaceuticals Co. Ltd. to Sapphire...
...of our healthcare solutions in China and other markets." Danehy declined to disclose how much Sapphire...
BioCentury | Nov 14, 2017
Company News

Pfizer ends JV with Hisun, names COO

...Pfizer Inc. (NYSE:PFE) sold its 49% stake in Chinese JV Hisun-Pfizer Pharmaceuticals Co. Ltd. to Sapphire...
...of our healthcare solutions in China and other markets." Danehy declined to disclose how much Sapphire...
BioCentury | May 26, 2017
Clinical News

CHMP recommends against Helsinn's Adlumiz

...to the recommendation. Helsinn gained the small molecule ghrelin agonist through its 2009 acquisition of Sapphire Therapeutics Inc....
BioCentury | Feb 17, 2017
Clinical News

Zuprata: Ph III SAPPHIRE started

...Clearside began the blinded, sham-controlled, U.S. Phase III SAPPHIRE trial to compare suprachoroidal Zuprata plus intravitreal...
BioCentury | Dec 7, 2015
Clinical News

Anamorelin regulatory update

...cancer (NSCLC) patients. Helsinn gained the small molecule ghrelin agonist through its 2009 acquisition of Sapphire Therapeutics Inc....
BioCentury | Oct 13, 2014
Clinical News

Anamorelin: Phase III data

...could not be reached for next steps. Helsinn gained anamorelin through its 2009 acquisition of Sapphire Therapeutics Inc....
Items per page:
1 - 10 of 105
BioCentury | Nov 20, 2020
Finance

Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable,  China deal for AUM-Newsoara and Qiming’s $1.2B fund

...company raises $91M series CMedable Inc. raised $91 million in a series C round led by Sapphire...
BioCentury | Nov 9, 2018
Clinical News

Clearside discontinues combo therapy for retinal vein occlusion

...retinal vein occlusion (RVO) after the combination missed the primary endpoint in the Phase III SAPPHIRE...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...Submit NDA YE18 Clearside Biomedical Inc. (NASDAQ:CLSD) Zuprata Retinal vein occlusion (RVO) Top-line Ph III SAPPHIRE...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...Biomedical Inc. (NASDAQ:CLSD) Triamcinolone acetonide Macular edema associated with retinal vein occlusion (RVO) Ph III SAPPHIRE...
BioCentury | Nov 17, 2017
Company News

Pfizer ends JV with Hisun

...Pfizer Inc. (NYSE:PFE) sold its 49% stake in Chinese JV Hisun-Pfizer Pharmaceuticals Co. Ltd. to Sapphire...
...of our healthcare solutions in China and other markets." Danehy declined to disclose how much Sapphire...
BioCentury | Nov 14, 2017
Company News

Pfizer ends JV with Hisun, names COO

...Pfizer Inc. (NYSE:PFE) sold its 49% stake in Chinese JV Hisun-Pfizer Pharmaceuticals Co. Ltd. to Sapphire...
...of our healthcare solutions in China and other markets." Danehy declined to disclose how much Sapphire...
BioCentury | May 26, 2017
Clinical News

CHMP recommends against Helsinn's Adlumiz

...to the recommendation. Helsinn gained the small molecule ghrelin agonist through its 2009 acquisition of Sapphire Therapeutics Inc....
BioCentury | Feb 17, 2017
Clinical News

Zuprata: Ph III SAPPHIRE started

...Clearside began the blinded, sham-controlled, U.S. Phase III SAPPHIRE trial to compare suprachoroidal Zuprata plus intravitreal...
BioCentury | Dec 7, 2015
Clinical News

Anamorelin regulatory update

...cancer (NSCLC) patients. Helsinn gained the small molecule ghrelin agonist through its 2009 acquisition of Sapphire Therapeutics Inc....
BioCentury | Oct 13, 2014
Clinical News

Anamorelin: Phase III data

...could not be reached for next steps. Helsinn gained anamorelin through its 2009 acquisition of Sapphire Therapeutics Inc....
Items per page:
1 - 10 of 105